Monograph
R03AK06 - Salmeterol and Fluticasone |
Propably not porphyrinogenic |
PNP |
Rationale
salmeterol: Substrate for CYP 3A4. Probably insignificant metabolic load. Fluticasone: Probably insignificant systemic exposure. Several references stating non-porphyrinogenic metabolism of glucocorticoids.
Chemical description
salmeterol Adrenergic administered in asthma in inhalation aerosol, 50 µg/dose. Gives rise only to very low plasma concentrations. Metabolized in the liver (CYP 3A4) producing several metabolites. fluticasone Antiasthmatic antiinflammatory glucocorticoide, administered as inhalation powder (50 - 250 µg/dose). Systemic exposure about 16% of the taken dose. Rapidly metabolized by CYP 3A4 (within 3-4 hours). glucocorticoides: EPI-list: safe French list: authorized South African list: use Kalman, Bonkowski: safe The Merck Manual: safe Tschudy DP, Lamon JM: safe Moore MR, Hift RJ: safe French list: authorized South African list: use
IPNet drug reports
Uneventful use reported in 7 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
